about us

We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class HDAC inhibitor, ME-344, a novel mitochondrial inhibitor, and ME-401, a highly selective PI3K delta inhibitor.
[ Read more ]

latest news

MEI Pharma Presents at BIO CEO & Investor Conference
[ Webcast ]

MEI Pharma Appoints Dr. Christine White as Chairman of the Board
[ December 10, 2015 ]

MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in AML, Plans to Initiate Phase III Registration Study
[ December 7, 2015 ]
[ AML Presentation ] [ MDS Presentation ]

MEI Pharma Hosts Annual Meeting of Stockholders
[ Webcast ]

Annual Review Cover
Click here for our 2015 Annual Review